- Open Access
Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors
© Kohler et al; licensee BioMed Central Ltd. 2009
- Received: 26 August 2009
- Accepted: 17 November 2009
- Published: 17 November 2009
With the aim to simplify cancer management, cancer research lately dedicated itself more and more to discover and develop non-invasive biomarkers. In this connection, circulating cell-free DNA (ccf DNA) seems to be a promising candidate. Altered levels of ccf nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) have been found in several cancer types and might have a diagnostic value.
Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls. To evaluate the applicability of plasma ccf nDNA and mtDNA as a biomarker for distinguishing between the three study-groups we performed ROC (Receiver Operating Characteristic) curve analysis. We also compared the levels of both species in the cancer group with clinicopathological parameters.
While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022). The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034). Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001).
Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management. However, ccf nDNA shows greater promise regarding sensitivity and specificity.
- Healthy Control Group
- Disease Group
- Benign Tumor Group
- Benign Disease Group
- Prenatal Medicine
In several branches of biomedical research the quest for new disease-related biomarkers has become one of the main objectives [1–3]. When it comes to discover and develop new biomarkers, oncology seems to be the most ambitious field. During the last few years a lot of research has been done identifying new cancer biomarkers with the aim to identify high risk individuals, detect cancer at an early stage, predict outcome, monitor treatment and screen for disease recurrence . In this respect the focus is now mainly directed towards the identification of non-invasive cancer biomarkers [5, 6].
In the case of breast cancer, there are only a few non-invasive biomarkers for screening, predicting prognosis and monitoring that have come to routine clinical application . Current established methods for routine breast cancer screening firstly encompass non-invasive methods including clinical breast examination and imaging techniques like mammography and ultrasonography . However, when pathological changes are suspected these techniques generally have to be followed by histopathological analysis for which invasive procedures, such as biopsies, are needed.
Lately, the discovery of circulating cell-free DNA (ccf DNA) has sparked the interest of scientists as it opens up a new possibility for non-invasive analysis of tumor derived genetic material. Both ccf nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) have become a matter of investigation and qualitative as well as quantitative alterations in these two determinants have been implicated in cancer . Changes in the level of ccf nDNA and mtDNA have been found in plasma and serum of patients with various cancer types [10, 11]. In breast cancer patients it has been shown that ccf nDNA levels are elevated in plasma as well as in serum when compared to healthy controls [12, 13]. On the other hand, mtDNA levels were mostly found to be decreased in breast cancer patients in comparison to healthy controls [14, 15].
To investigate the potential of ccf nuclear and mitochondrial DNA as a marker for clinical application we examined the level of both species in malignant and benign tumor groups and healthy controls.
The study was performed at the Laboratory for Prenatal Medicine and Gynecological Oncology/Department of Biomedicine, Women's Hospital Basel and approved by the local institutional review board (Ethic commission beider Basel). Written consent forms were collected from all patients who were involved in this study.
Study cohort and sampling procedure
The blood samples used in this study were collected in a time period from 2005 to 2007 in either the Women's Hospital of the University of Basel or the Women's Hospital of Liestal. In total 148 women were included in the study. Most of the women were European Caucasians. All blood samples were taken before any surgical interventions or therapeutic treatments. Patients' data (age, tumor size, lymph node involvement, extent of metastasis, estrogen receptor, progesterone receptor and Her2neu - status) were obtained from the pathological reports. The blood samples were processed and the DNA was extracted according to a standardized protocol as previously described elsewhere . DNA was quantified using a Nanodrop spectrophotometer (Thermo scientific).
The study cohort (n = 148) was divided into 3 groups: 1) malignant disease group (n = 52); 2) benign disease group (n = 26) and 3) healthy control group (n = 70). For groups 1 and 2 the diagnoses were all biopsy-confirmed. The healthy control group used in this study neither had a history of cancer nor suffered from any other severe diseases.
For the simultaneous quantification of ccf nDNA and mtDNA from plasma a multiplex qPCR was performed using the Glyceraldehyd-3-phosphat-dehydrogenase (GAPDH) and the mtDNA encoded ATPase 8 (MTATP 8) reference genes.
Quantitative PCR (qPCR) for GAPDH and MTATP8
Sequences of primers and probes (5' → 3')
Length of primer/probe
Amplicon lengths (bp)
CCC CAC ACA CAT GCA CTT ACC
CCT AGT CCC AGG GCT TTG ATT
(MGB) TAG GAA GGA CAG GCA AC (VIC)
AAT ATT AAA CAC AAA CTA CCA CCT ACC
TGG TTC TCA GGG TTT GTT ATA
(MGB) CCT CAC CAA AGC CCA TA (FAM)
qPCR was carried out in 25 μl of total reaction volume containing 7 μl H2O, 12.5 μl TaqMan® Universal PCR Master Mix (Applied Biosystems, Branchburg, New Jersey, USA), 0.75 μl of each of the above mentioned 10 μM primers (Microsynth, Balgach, Switzerland), 1 μl of a 5 μM FAM-labeled MTATP 8-probe and 0.5 μl of a 5 μM VIC-labeled GAPDH-probe (both probes from Applied Biosystems, Rotkreuz, Switzerland). For each reaction 1 μl of DNA was added. qPCR was performed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Branchburg, New Jersey, USA) under the following conditions: an initiation step for 2 minutes at 50°C is followed by a first denaturation for 10 minutes at 95°C and a further step consisting of 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.
Data collection and processing
For the calculation of the concentration (c) in genome equivalents (GE/mL) the DNA quantity (Q) obtained by qPCR was multiplied with one fraction consisting of the volume of eluted DNA (VDNA; 80 μl/sample) divided by the sample volume used for PCR (VPCR; 2.5 μl/reaction) resulting in a factor of 32 and with another fraction consisting of the unit (1 ml) divided by the volume of extracted plasma (VEX = 400 μl) resulting in a factor of 2.5.
The content of mtDNA was calculated using the delta Ct (ΔCt) of an average Ct of mtDNA and nDNA (ΔCt = CtnDNA - CtmtDNA) in the same well as an exponent of 2 (2ΔCt). Relative quantities of ccf mtDNA could be estimated using an equation of GE (nDNA) × fold-change mtDNA and expressed also as GE per mL of plasma.
All statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, USA). The normality distribution of the data was determined using the Shapiro-Wilk-Test. The data were not normally distributed. For comparison of ccf nDNA and mtDNA levels between the three groups (malignant disease group, benign disease group and healthy control group) the Mann-Whitney-U-Test was performed. For the comparison of the ccf nDNA and mtDNA levels with other established prognostic factors the Mann-Whitney-U-Test and the Kruskal-Wallis-Test were used. P-values ≤ 0, 05 were considered statistically significant.
Comparison of plasma ccf nDNA and mtDNA levels between the three study-groups
We compared the levels of plasma ccf nDNA and mtDNA, analyzed by multiplex real-time PCR, between the malignant disease group, the benign disease group and the healthy control group. The level of ccf nDNA in the malignant disease group was significantly higher in comparison with the benign disease group (4678 vs. 1359, Mann-Whitney: P < 0.001) and the healthy control group (4678 vs.1298, Mann-Whitney: P < 0.001). No significant difference could be found in the level of nDNA between the benign disease group and the healthy controls (1359 vs. 1298 Mann-Whitney: P = 0.830).
Concentrations (GE/mL) of plasma ccf nDNA and ccf mtDNA in the 3 study-groups; expressed as median.
Total no. of patients
(mean ± S.D.)
Median Ccf nDNA(GE/mL)
Median Ccf mtDNA (GE/mL)
Malignant disease group
64 ± 15
Benign disease group
41 ± 16
53 ± 14.6
Correlation between the level of plasma ccf nDNA and mtDNA with clinicopathological parameters
For the malignant disease group, the association between the level of ccf DNA and other established clinical parameters, including tumor size, lymph node involvement, extent of metastasis and the status of estrogen receptor (ER), progesterone receptor (PR) and Her2/neu were analyzed.
Association between plasma ccf DNA level and tumor size in the malignant disease group
Association between plasma ccf DNA level and lymph node involvement, extent of metastasis, receptor status of ER, PR and Her2/neu amplification in the malignant disease group
In the malignant disease group no statistical significance in the level of ccf nDNA nor mtDNA between node negative and node positive patients, extent of metastasis and receptor status of ER, PR and Her2/neu amplification could be found.
The applicability of plasma ccf nDNA and mtDNA as marker for the discrimination between the three study groups
To evaluate the applicability of ccf plasma nDNA and mtDNA as a marker for distinguishing between malignant disease group, benign disease group and healthy control group, we performed ROC (Receiver Operating Characteristic) curve analysis. For the identification of the optimal cut-off point we used the Youden index (J). J is the maximum vertical distance between the ROC-curve and the diagonal reference line and is defined as J = maximum (sensitivity) + (specificity) - 1. The Youden index allows the selection of an optimal cut-off point under the assumption that sensitivity and specificity are equally weighted .
ROC curve analysis using ccf nDNA for the discrimination between the malignant disease group and the healthy control group
ROC curve analysis using ccf mtDNA for the discrimination between the breast tumor group and the healthy control group
Decreased levels of ccf mtDNA was found in both the benign disease group and the malignant disease group when compared to the healthy control group. For discriminating between the breast tumor group (malignant and benign) and the healthy control group an optimal cut-off point was indicated at 463282 GE/ml for ccf nDNA with a sensitivity 53% and a specificity of 87% (AUC = 0.68, P < 0.001, 95% confidence interval = 0.589-0.768). The ROC-curve for discrimination between the breast tumor group and the healthy control group using ccf mtDNA is shown in Fig. 3.
According to our knowledge, our study is the first to find increased levels of ccf nDNA and simultaneously decreased levels of ccf mtDNA in plasma samples from patients with breast tumor compared to healthy controls. The former shows a probable diagnostic value in discriminating between breast cancer and healthy controls with a sensitivity of 81% and specificity of 69%, the latter reveals possible relevance in distinguishing between breast tumors (malignant and benign) and normal controls with a sensitivity of 53% and specificity of 87%.
For ccf nDNA, our previous studies indicated that in comparison with other potential circulating biomarkers involved in malignancy, such as nucleosomes, vascular endothelial growth factor (VEGF) and its soluble receptor (sVEGFR1), the ccf DNA showed more sensitivity and specificity in discriminating between breast cancer and normal controls [19, 20]. Recently, Diehl et al, explored the possibility of using ccf tumor derived DNA for the management of colorectal cancer . Patients with detectable ccf tumor DNA suffered from relapse, whereas subjects without ccf tumor DNA did not experience tumor recurrence. The ccf tumor DNA detection seems to be more reliable for predicting relapse than the standard biomarker, carcinoembryonic antigen (CEA), used for the management of colorectal cancer . It was also reported that the levels of ccf DNA could be changed after therapy in breast cancer [23, 24]. The observations suggest that determination of ccf DNA in cancer may prove a useful tool in the management of the condition.
In this study, we found high levels of ccf plasma DNA related to tumor size. This finding can be supported by investigations in the field of prenatal medicine. Placenta has been regarded as "pseudomalignant" and placental derived ccf fetal DNA in maternal circulation can be used for risk-free prenatal diagnosis [25–27]. The concentration of placental derived ccf fetal DNA in maternal blood increases with the progress in gestational weeks and with respect to placental size . Using fetal specific DNA sequences, ccf fetal DNA could be detected from the 5th gestational week, and the results were reliable by the 8th gestational week with an accuracy of 100% in fetal DNA determination [29, 30]. The results imply that by using tumor specific genetic alterations as marker, tumor derived ccf DNA may be detectable at an early stage with confined tumor growth and size.
For mtDNA, both down-or up-regulation in cancer patients has been shown in the past, and many attempts to explain both events have been made. While up-regulation of mtDNA in cancer patients was only demonstrated in a few cases , many studies including this one found decreased mtDNA levels in cancer patients [32, 33]. One explanation for lower mtDNA copy numbers in cancer patients might be ascribed to mutations or deletions occurring as a consequence of exposure of mtDNA to reactive oxygen species (ROS) which are a by-product of respiration and oxidative phosphorylation. Especially in the D-Loop region which controls replication and transcription of mtDNA, such mutations and deletions may lead to changes in transcription and replication rate and finally result in a decrease of mtDNA levels in cancer patients . In this study we found lower levels of mtDNA in the benign group when compared with the cancer group. In benign tumors depletion of mtDNA could be a mechanism of tumor cells to escape apoptosis and to finally promote cancer progression . On the other hand, the relative increase of mtDNA levels in the cancer group compared to the benign disease group might be a compensatory mechanism of the cells to respond to the decline in respiratory function .
We showed that levels of ccf nDNA where significantly elevated in breast cancer patients in comparison with a benign disease group and a healthy control group, while levels of ccf mtDNA were significantly elevated in the breast tumor group (malignant and benign) when compared to the healthy control group. Regarding ccf nDNA levels, our results are confirmed by the findings of other studies which also found altered levels of ccf nDNA in cancer patients. For ccf mtDNA however, both down- as well as upregulation of ccf mtDNA levels in cancer patients have been reported and therefore grant further investigations of mtDNA content in different cancer and tumor types, in order to clearly establish whether mtDNA levels are cancer type or tumor specific.
To conclude, both ccf nDNA and mtDNA levels allowed for discrimination between the different study groups. While ccf nDNA could be used for discriminating between patients with breast cancer and healthy controls, ccf mtDNA could be used for distinguishing between patients with breast tumors (malignant and benign) and healthy controls. Altogether this suggests that ccf nDNA has potential as a cancer specific biomarker, whereas ccf mtDNA may rather serve as a tumor biomarker.
This work was supported in part by Swiss National Science Foundation (320000-119722/1) and Swiss Cancer League, Krebsliga Beider Basel and Dr Hans Altschueler Stiftung. We thank Caroline Hyde for proofreading the manuscript and Vivian Kiefer and Nicole Chiodetti for their help.
- Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006, 355 (25): 2631-9. 10.1056/NEJMoa055373View ArticlePubMedGoogle Scholar
- Antoniades CA, Barker RA: The search for biomarkers in Parkinson's disease: a critical review. Expert Rev Neurother. 2008, 8 (12): 1841-52. 10.1586/14737188.8.131.521View ArticlePubMedGoogle Scholar
- Chou YY, Lepore N, Avedissian C, Madsen SK, Parikshak N, Hua X: Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage. 2009, 46 (2): 394-410. 10.1016/j.neuroimage.2009.02.015PubMed CentralView ArticlePubMedGoogle Scholar
- Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E: Cancer biomarkers: a systems approach. Nat Biotechnol. 2006, 24 (8): 905-8. 10.1038/nbt0806-905View ArticlePubMedGoogle Scholar
- Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L: Intensive post-operative follow-up of breast cancer patients with tumor markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006, 6: 269- 10.1186/1471-2407-6-269PubMed CentralView ArticlePubMedGoogle Scholar
- Martinez L, Castilla JA, Blanco N, Peran F, Herruzo A: CA 125, CA 15.3, CA 27.29, CEA, beta-hCG and alpha-fetoprotein levels in cyst fluid of breast macrocysts. Int J Gynaecol Obstet. 1995, 48 (2): 187-92. 10.1016/0020-7292(94)02279-8View ArticlePubMedGoogle Scholar
- Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M: Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumor Biol. 2005, 26 (6): 281-93. 10.1159/000089260. 10.1159/000089260View ArticleGoogle Scholar
- Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M: Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008, 299 (18): 2151-63. 10.1001/jama.299.18.2151PubMed CentralView ArticlePubMedGoogle Scholar
- Tseng LM, Yin PH, Chi CW, Hsu CY, Wu CW, Lee LM: Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer. 2006, 45 (7): 629-38. 10.1002/gcc.20326View ArticlePubMedGoogle Scholar
- Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT: Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta. 2002, 321 (1-2): 77-87. 10.1016/S0009-8981(02)00091-8View ArticlePubMedGoogle Scholar
- Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X: Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol. 2008, 112 (4): 843-50.View ArticlePubMedGoogle Scholar
- Zanetti-Dallenbach R, Wight E, Fan AX, Lapaire O, Hahn S, Holzgreve W: Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res. 2008, 28 (2A): 921-5.PubMedGoogle Scholar
- Zanetti-Dallenbach RA, Schmid S, Wight E, Holzgreve W, Ladewing A, Hahn S: Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers. 2007, 22 (2): 95-9.PubMedGoogle Scholar
- Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY: Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer. 2006, 95 (8): 1087-91. 10.1038/sj.bjc.6603377PubMed CentralView ArticlePubMedGoogle Scholar
- Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC: Tumor-specific changes in mtDNA content in human cancer. Int J Cancer. 2005, 116 (6): 920-4. 10.1002/ijc.21110View ArticlePubMedGoogle Scholar
- Zhong XY, Ladewig A, Schmid S, Wight E, Hahn S, Holzgreve W: Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet. 2007, 276 (4): 327-31. 10.1007/s00404-007-0345-1View ArticlePubMedGoogle Scholar
- Xia P, Radpour R, Zachariah R, Fan AXC, Kohler C, Hahn S, Holzgreve W, Zhong XY: Simultaneous quantitative assessment of circulating cell-free mitochondrial and nuclear DNA by multiplex real-time PCR. Genetics and Molecular Biology. 2009, 32 (1): 20-4. 10.1590/S1415-47572009000100003. 10.1590/S1415-47572009000100003PubMed CentralView ArticlePubMedGoogle Scholar
- Akobeng AK: Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr. 2007, 96 (5): 644-7. 10.1111/j.1651-2227.2006.00178.xView ArticlePubMedGoogle Scholar
- Seefeld M, El Tarhouny S, Fan AX, Hahn S, Holzgreve W, Zhong XY: Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors. Int J Biol Markers. 2008, 23 (2): 69-73.PubMedGoogle Scholar
- El Tarhouny S, Seefeld M, Fan AX, Hahn S, Holzgreve W, Zhong XY: Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine. 2008, 44 (1): 65-9. 10.1016/j.cyto.2008.06.008View ArticlePubMedGoogle Scholar
- Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M: Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008, 14 (9): 985-90. 10.1038/nm.1789PubMed CentralView ArticlePubMedGoogle Scholar
- Catarino R, Ferreira MM, Rodrigues H, Coelho A, Nogal A, Sousa A: Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 2008, 27 (8): 415-21. 10.1089/dna.2008.0744View ArticlePubMedGoogle Scholar
- Deligezer U, Eralp Y, Akisik EZ, Akisik EE, Saip P, Topuz E: Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. Ann N Y Acad Sci. 2008, 1137: 175-9. 10.1196/annals.1448.010View ArticlePubMedGoogle Scholar
- Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E: Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med. 2008, 46 (3): 311-7. 10.1515/CCLM.2008.080View ArticlePubMedGoogle Scholar
- Zhong XY, Hahn S, Holzgreve W: Prenatal identification of fetal genetic traits. Lancet. 2001, 357 (9252): 310-1. 10.1016/S0140-6736(05)71754-2View ArticlePubMedGoogle Scholar
- Zhong XY, Holzgreve W, Hahn S: Risk free simultaneous prenatal identification of fetal Rhesus D status and sex by multiplex real-time PCR using cell free fetal DNA in maternal plasma. Swiss Med Wkly. 2001, 131 (5-6): 70-4.PubMedGoogle Scholar
- Zhong XY, Holzgreve W, Hahn S: Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia. Ann N Y Acad Sci. 2001, 945: 138-40.View ArticlePubMedGoogle Scholar
- Lo YM: Fetal DNA in maternal plasma: biology and diagnostic applications. Clin Chem. 2000, 46 (12): 1903-6.PubMedGoogle Scholar
- Deng Z, Wu G, Li Q, Zhang X, Liang Y, Li D: Noninvasive genotyping of 9 Y-chromosome specific STR loci using circulatory fetal DNA in maternal plasma by multiplex PCR. Prenat Diagn. 2006, 26 (4): 362-8. 10.1002/pd.1422View ArticlePubMedGoogle Scholar
- Deng ZH, Li Q, Wu S, Li DC, Yang BC: [Application of 17 Y-chromosome specific STR loci in paternity testing]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008, 16 (3): 699-703.PubMedGoogle Scholar
- Mizumachi T, Muskhelishvili L, Naito A, Furusawa J, Fan CY, Siegel ER: Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate. 2008, 68 (4): 408-17. 10.1002/pros.20697PubMed CentralView ArticlePubMedGoogle Scholar
- Selvanayagam P, Rajaraman S: Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma. Lab Invest. 1996, 74 (3): 592-9.PubMedGoogle Scholar
- Jiang WW, Rosenbaum E, Mambo E, Zahurak M, Masayesva B, Carvalho AL: Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res. 2006, 12 (5): 1564-9. 10.1158/1078-0432.CCR-05-1471View ArticlePubMedGoogle Scholar
- Lee HC, Hsu LS, Yin PH, Lee LM, Chi CW: Heteroplasmic mutation of mitochondrial DNA D-loop and 4977-bp deletion in human cancer cells during mitochondrial DNA depletion. Mitochondrion. 2007, 7 (1-2): 157-63. 10.1016/j.mito.2006.11.016View ArticlePubMedGoogle Scholar
- Higuchi M: Regulation of mitochondrial DNA content and cancer. Mitochondrion. 2007, 7 (1-2): 53-7. 10.1016/j.mito.2006.12.001PubMed CentralView ArticlePubMedGoogle Scholar
- Barrientos A, Casademont J, Cardellach F, Estivill X, Urbano-Marquez A, Nunes V: Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res. 1997, 52 (2): 284-9. 10.1016/S0169-328X(97)00278-7View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.